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Hepatitis A virus (HAV) is classified as Hepatovirus within the Picornaviridae.
1
In virology, HAV is a positively stranded ribonucleic acid (RNA) virus of about
7,500 nucleotides.
2 The viral capsid is composed of three exposed polypeptides
VP1, VP2, VP3, and a putative VP4, with a highly conserved antigenic structure.
3
HAV is transmitted through fecal to oral route and is diagnosed by positive serum
IgM anti-HAV antibody test. Isolates of HAV are of a single serotype, but human
isolates can be categorized into three genotypes (I, II and III) with 2 subgenotypes
(A and B for I and III). Genotype I is the most abundant type worldwide, and
particularly IA is found in North America, Europe, China, Japan, the former
USSR and Thailand. Strains of subgenotype IIIA have been collected from
humans infected with HAV in India, Sri Lanka, Nepal, Malaysia and the USA.
3,4
For the past several years, studies on HAV have not been performed because most
people in Korea carry the HAV antibody by natural infection. Once HAV
antibodies are acquired, they give life-long immunity. Moreover, hepatitis A
infection is usually mild in children, and rarely progresses into chronicity and
fulminant hepatitis.
5,6 However, the high risk for HAV infection in Korea has been
focused on young adults and adolescents who, did not get infected in childhood
due to improved hygiene measures, and are more prone to infection later in life
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INTRODUCTIONwith more serious disease.
7-9 In 2001, sporadic acute
hepatitis A was reported in Korea, being subgenotype IA.
7
In 2007, an outbreak of acute hepatitis A in a Korean
hospital was reported, and the subgenotypes of this hepa-
titis A virus were found to be IA and IB.
10
HAV phylogenetic studies can provide important infor-
mation for the design of appropriate public health cares
and HAV genotypic changes. Therefore, we investigated
the genotypes of recently isolated HAV cases in the south-
east area of Gyeonggi-do in Korea.
Patients and collection of blood samples
From June 2004 to June 2006, 46 patients from the Bundang
CHA Hospital were identified prospectively. All patients,
showing clinical and biochemical signs of acute hepatitis A
and serological evidence of acute hepatitis A, were
classified as acute hepatitis A patients. The serological
evidence was obtained with IgM anti-HAV antibody tests
(EIA, VIDAS, BioMérieux, Marcy-I’Etoile, France).
Patients lived in the south-east area of Gyeonggi-do
(Seongnam-si, Icheon-si, Gwangju-si) in Korea and all
were Koreans. 
During the two study years, there was no reported
outbreak of acute hepatitis A in the study area. Routine
contact tracing was done. All patients visited a hospital as
an outpatient once a week for two or three weeks. All cases
were sporadic acute hepatitis A. 
Ten mL of whole blood was collected from the veins of
each patient in order to analyse the genotype of HAV.
Each sample was numbered in order of date. The whole
blood was centrifuged to separate the serum. The serum
was preserved at -20˚C. For the study, sera of the enrolled
patients were numbered from 1 to 46. The study was
approved by the local ethical committee and conform to
ethical guidelines of the Declaration of Helsinki. Informed
consent was obtained from each patient enrolled in the
study.
First-strand cDNA synthesis
Viral RNAs extracted from serum using Viral-spin
TM
(Intron, Korea) were used for the synthesis of first-strand
complementary DNAs (DNAs) by reverse transcriptase.
Reverse transcription was performed for 1.5 h at 42˚C in a
final reaction volume of 20 µL containing 7.5 µL of the
purified total RNA, 4 µL of 5 × reaction buffer (Promega,
Madison, WI, USA), 5 µL of dNTPs (each 2 mM), 2 µL of
10 µM hexamer, 0.5 µL of RNasin
® RNase Inhibitor (40
U/µL; Promega), and 1 µL of Moloney murine leukemia
virus reverse transcriptase (200 U/µL; Promega).
Target PCR
The cDNA obtained was amplified by poly chain reaction
(PCR) by using oligonucleotides, designed on the basis of
sequence alignments.
12 PCR was performed for 40 cycles
(0.5 min at 94˚C, 1.5 min at 50˚C, and 1.5 min at 72˚C) in
a final reaction volume of 20 µL containing 5 µL of the
cDNA reaction mixture, 0.5 µM each primer and 10 µL 2X
master mix (Seegene).
Cloning & sequencing
The target PCR products within the agarose gel were
purified for sequencing using the QIAquick
® PCR
purification kit (QIAGEN) and cloned into a TOPO TA
cloning vector (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s instructions. The cloned plasmids
were sequenced in ABI PRISM
® 3100 Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA).
Direct sequencing
The target PCR products were re-amplified and extracted
from the gel using the GENCLEAN II Kit (Q-BIO gene,
Carlsbad, CA, USA), and directly sequenced with ABI
PRISM
®3100-Avant Genetic Analyzer (Applied Biosy-
stems, Foster City, CA, USA) using a HAV specific primer
(5’-GTCTACCAGGCATTCGCTTCAT-3’).
Phylogenetic analysis and genotype determination 
The CLUSTAL W (version 1.83) program was used to
generate the phylogenetic tree. The putative VP1/2A
junction sequences were amplified and sequenced from
clinical samples and compared with the corresponding
Gene Bank reference sequences for genotypes. IA :
AF234864 (KU97-1), AF234876 (KU98-42), AB020567,
L07717 (PRC37). IB : L07700 (Ag11). II : L07693 (CF-
53). IIIA : AJ299467 (NOR-24), L07668 (GA76), L07688
(H-122), L07725 (India90), L20530 (A-177). IIIB :
L07729 (SLF88). The amino acid alignments of the putative
VP1/P2A junction in this study summitted to Genebank
were numbered : FJ372930 - FJ372970. 
Forty six patients were enrolled in this study. Among the
total 46 patients, 21 were male and 25 were female. The
mean age was 31 ± 6 years. The mean period of hospitali-
zation was 11 ± 6 days. The baseline clinical and labora-
tory results are summarized in Table 1. Most clinical and
laboratory results of each genotype did not show differences
between the genotypes. Case of co-infection with HBV or
HCV was not found. The yearly distribution according to
genotype is shown in Table 2. 
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MATERIALS AND METHODS
RESULTS We found that sera from 41 out of 46 patients were
positive for HAV-RNA. As can be seen in the phyloge-
netic tree, the HAV sequrences from 25 patients (60%) out
of 41 ones were found to be of subgenotype IIIA , and
HAV sequences from 16 patients (40%) were confirmed
as subgenotype IA (Fig. 1). Compared to the formerly
reported subgenotype IA in Korea,
7 the subgenotype IA in
our investigation showed > 95% sequence homology.
Several amino acid substitutions were found in subgeno-
type IA and IIIA. The 2A-19 substitution was found in ten
samples of subgenotype IA. The substitution of 2A-19 is
identical to fulminant hepatitis of AB020567 in Japan. On
the serum No. 37, glutamic acid of 2A-11, on L07717 and
L07716 found in China was substituted by aspartic acid.
On the serum No. 26, arginine of 2A-6, on L20550 found
in Japan was substituted by glycine. 
On serum No. 18 of subgenotype IIIA, valine of VP1-
288 was substituted by arginine. On serum No. 45, gluta-
mine of 2A-25 was substituted by arginine. On serum No.
7 and 36, methionine of VP1-276 was substituted by
arginine. On serum No. 9, methionine of VP1-276 was
substutited by leucine, and aspartatic acid of VP1-283 was
substituted by glycine. On serum No. 10, lysine of 2A-18
was substituted by glutamic acid.
The founding works on HAV genetic variability made use
of discrete, selected partial HAV genomic regions, such as
the C terminus of VP3 to the N terminus of VP1 or the
putative VP1/P2A junction region. HAV genotype is defi-
ned as a group of viruses with > 85% nucleotide sequence
identity within one of these regions. Genotypes I and III
are further subdivided into two distinct subgroups, which
differ in sequence in no more than 7.5% of base posi-
tions.
3,4,11 The subgenotypes, IA and IB have been reported
in Korea.
7,10 In conclusion, the three genotypes (IA, IB,
IIIA) are co-circulating in Korea. It has been reported before
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Table 2. Yearly Distribution of HAV-RNA Detected Acute 
Hepatitis A Patients 
Genotype Genotype 
Total
IA IIIA
June 2004 to June 2005  4 10 14
July 2005 to June 2006  12 15 27
Total 16 25 41
HAV-RNA, Hepatitis A virus-ribonucleic acid.
DISCUSSION
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Fig. 1. Phylogenetic relationship of HAV gene from DNA extracted with known
reference sequences by neighbor-joining analysis using CLUSTAL W (1.83).
Bootstrap values above 80% from 100 replicates are also shown (L07700 is
genotype IB, L07693 is genotype II, L07729 is genotype IIIB). 
Table 1. Baseline Clinical and Laboratory Results of 46 
Hospitalized Patients with Positive IgM Anti HAV Test
Variable Total
Number 46
Age (yrs) 31 ± 6
Period of hospitalization (days) 11 ± 6
AST on admission (IU/L) 2383 ± 2523
Peak AST (IU/L) 2589 ± 2669
ALT on admission (IU/L) 2587 ± 1415
Peak ALT (IU/L) 2809 ± 1544
TB on admission (mg/dL) 5.1 ± 1.9
Peak TB (mg/dL) 6.6 ± 3.3
Platelet (cells/mm
3) 168000 ± 73000
PT (%) 75 ± 25
Albumin (g/dL) 3.7 ± 0.4
AST, aspartate aminotransferase; ALT, alanine aminotransferase; HAV, 
Hepatitis A virus; IgM, immunoglobulin M; PT, prothrombin time; TB, total
bilirubin. 
Values represent mean ±standard deviation.that genetic changes are rare in the HAV genome, which is
unlike other RNA viruses.
12 Also, nationwide research of
HAV genotypic distribution in Korea has not yet been
performed. It can be hypothesized that the influx from the
other regions of Korea or predominant countries is one of
the causes in the subgenotype IIIA circulating in Korea. It
was reported that the dominant HAV genotype in India,
Sri Lanka, Nepal, and Malaysia is IIIA, even though the
research was insufficient.
13 Recent reports showed that the
HAV subgenotype IIIA in those countries has continu-
ously been the circulating type.
14,15 The acute hepatitis A
samples gathered from this research area and subgenotype
IIIA dominant country need to be compared by further
molecular analysis. To verify possible infection from travel,
41 patients, detected with HAV-RNA, were questioned
about their travel history. One patient (No. 22, subgenotype
IA) had a travel history to Philippines 15 days before
hospitalization. Tjon et al.
17 reported that HAV subgenotype
IIIA was found in homeless, bad hygiene patients and
intravenous drug users. However, these trends were not
found in this research.
The outbreak of HAV subgenotype IIIA has been
reported among intravenous drug users in Europe.
16-18 Up
to date, HAV has been known to be transmitted through
fecal to oral route. However, by the outbreak of the sub-
genotype IIIA of intravenous drug users and infection of
HAV in hemophilia patients by clotting factor,
19 it can be
possible that HAV is also transmitted by the parenteral
route. This change of mode of transmission is likely due to
nucleotide variability that reach 4% of the subgenotype
IIIA, and it is also possible that HAV has high selection
pressure through fecal to oral route and infection through
blood has low selection pressure.
20,21 The nucleotide varia-
bility of the HAV subgenotype IIIA needs to be studied
through continuous molecular study in Korea. Through the
research, future outbreaks of the subgenotype IIIA in
intravenous drug users and blood products can be predicted.
Little information is available on the possible relation
between the severity of hepatitis A and the infecting geno-
type.
22,23 It was previously considered that HAV disease
severity is linked to individual host factors such as age and
underlying liver disease. However, through continuous
investigation of HAV, many factors that affect the severity
of acute hepatitis A have been proven. First, it has been
reported that nucleotide variations in the central portion of
the 5’ NTR of HAV could affect the severity of acute
hepatitis A.
24 Low or undetectable HAV viral load and a
high bilirubin level could independently affect the progres-
sion to fulminant hepatitis. It has also been reported that
HAV genotype did not affect the progress to fulminant
hepatitis.
23 The present study found also similar number of
subgenotypes IA and IIIA in the same research area, thus
making it possible to directly compare their clinical and
laboratory results. Most clinical and laboratory results of
each genotype did not reveal any differences between the
genotypes, but it showed that mean peak total bilirubin
(TB) level in subgenotype IIIA is significantly higher (data
not shown). Also, the mean TB level on admission showed
a high level of tendency on subgenotype IIIA, even though
it is not statistically significant. However, difference has
limitations, mostly stemming from this study’s small
sample size, small area of study and selection of patients.
Future work is required to ascertain the difference of total
bilirubin according to genotype. 
The nucleotide sequence heterogeneity found in our
study of the HAV genome of these 41 virus strains results
in only limited differences in the amino acid sequence.
Among all of the subgenotype IA and IIIA, amino acid
sequence differences showed to be maximum 3% (2/56).
On the former prevalent subgenotype IA of Korea, it was
reported that lysine 2A-10 was substituted by arginine, and
glutamine 2A-19 by serine.
7 However, our study showed
that substitution of 2A-10 did not occur in every sample,
and substitution of 2A-19 occurred only in 10 of 16 patients
who showed subgenotype IA.
In conclusion, this study examined HAV subgenotype
IIIA in Korea, and the results showed that three HAV
subgenotypes (IA, IB, IIIA) co-circulate in Korea. The
genetic relatedness of HAV from Korea provides valuable
new data on the distribution of subgenotype IIIA.
This in part was presented at APASL2007 poster presen-
tation. 
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